       Document 0164
 DOCN  M9610164
 TI    [Multidrug-resistant tuberculosis. Epidemiology, treatment, prevention
       and diagnostic research]
 DT    9601
 AU    Perronne C; de Truchis P; Service des maladies infectieuses et
       tropicales, hopital; Raymond-Poincare, Garches, France.
 SO    Rev Med Interne. 1995;16(7):547-52. Unique Identifier : AIDSLINE
       MED/96008894
 AB    The recent augmentation of the prevalence of multidrug resistant (MDR)
       tuberculosis is related to the high incidence of tuberculosis in HIV
       infected people, especially in those with low social status and no
       medical care; several nosocomial epidemics of MDR tuberculosis were
       observed in American and European institutions where HIV-infected
       persons were hospitalized; these MDR tuberculosis were associated with a
       high mortality-rate and frequent nosocomial transmission to
       immunocompromised contacts and care workers. The rapid institution of an
       adequate treatment with ancient antituberculosis agents (cycloserin,
       capreomycin, aminoglycosides) and/or new drugs (rifabutine, ofloxacin,
       sparfloxacin, etc) is necessary to avoid mortality and to diminish
       transmission. Prevention of MDR tuberculosis transmission is very
       important: patient isolation, adequate and prolonged therapy, better
       detection of resistance with gene-amplification methods (PCR) which are
       under investigation.
 DE    Comorbidity  Cross Infection/EPIDEMIOLOGY  English Abstract
       France/EPIDEMIOLOGY  Human  HIV Infections/EPIDEMIOLOGY  Polymerase
       Chain Reaction  *Tuberculosis,
       Multidrug-Resistant/DIAGNOSIS/EPIDEMIOLOGY/THERAPY  JOURNAL ARTICLE
       REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

